Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

DFT383 bei pädiatrischen Teilnehmern mit nephropathischer Cystinose (CYStem)

15. Oktober 2026 aktualisiert von: Novartis Pharmaceuticals

Eine Open-Label-Studie mit mehreren Zentrum, Phase I/II zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit von DFT383 bei pädiatrischen Teilnehmern mit nephropathischer Cystinose

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.

The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.

This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.

The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.

Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.

The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.

Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.

Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

  • Name: Novartis Pharmaceuticals

Studienorte

    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85016
        • Rekrutierung
        • Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
        • Kontakt:
        • Hauptermittler:
          • Shanna White
    • California
      • San Diego, California, Vereinigte Staaten, 92123
        • Rekrutierung
        • University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
        • Kontakt:
        • Hauptermittler:
          • Nadine Benador nbenador@health.ucsd.edu
      • Stanford, California, Vereinigte Staaten, 94305
        • Rekrutierung
        • Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
        • Hauptermittler:
          • Alice Bertaina
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Rekrutierung
        • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
        • Hauptermittler:
          • Laurence (Larry) Greenbaum
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia (Recruiting Cohort 0)
        • Kontakt:
          • Melissa Cadnapaphornchai
          • Telefonnummer: 215-590-2449
        • Hauptermittler:
          • Melissa Cadnapaphornchai
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
        • Kontakt:
        • Hauptermittler:
          • Ewa Elenberg

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre bis 5 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Informed consent in writing from parent(s) or legal guardian(s) must be provided
  2. 2 to 5 years of age (including 5 years and 364 days old) at Screening
  3. Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  4. Oral cysteamine therapy for at least 6 months
  5. Historic clinical diagnosis of nephropathic cystinosis
  6. Laboratory evidence of of renal fanconi syndrome (RFS)
  7. Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  8. Received all age-appropriate vaccinations

Key exclusion Criteria for Cohort 1 and 0

  1. A history of kidney transplantation
  2. A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  3. History of malignancy
  4. A severe or uncontrolled medical disorder
  5. Major surgery within 90 days

Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:

1. Indomethacin within 2 weeks prior to Screening

Other protocol-defined inclusion/exclusion criteria may apply.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort 1 (DFT383)

Treatment with DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

Kein Eingriff: Cohort 0 (SoC)

No study treatment, will continue with standard of care (cysteamine).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Core Phase - Incidence of adverse events (Cohort 1)
Zeitfenster: Up to 32 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 32 months
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Zeitfenster: 42 days post DFT infusion

Hematological reconstitution by Day 42 post-DFT383 infusion

42 days post DFT infusion
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Zeitfenster: Up to 32 months

Proportion of participants with reversal of renal Fanconi syndrome (RFS)

Up to 32 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Core Phase - Number of participants independent from cysteamine
Zeitfenster: up to 24 months

Independence from oral and ophthalmic cysteamine

up to 24 months
Core Phase - Health-related quality of life (HRQOL)
Zeitfenster: Up to 32 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 32 months
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Zeitfenster: Up to 24 months

Time from infusion to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Zeitfenster: Up to 24 months

Time from screening to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Duration of reversal of RFS
Zeitfenster: Up to 24 months

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Zeitfenster: Up to 27 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 27 months
Core Phase - Change from baseline on urine amino acids
Zeitfenster: Up to 27 months

Change from baseline on urine amino acids

Up to 27 months
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Zeitfenster: Up to 27 months

Change from baseline on urinary glucose to creatinine ratio

Up to 27 months
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Zeitfenster: Up to 27 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 27 months
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Zeitfenster: Up to 27 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 27 months
Core Phase - Number of participants with improvement of proximal tubular function
Zeitfenster: Up to 27 months

Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization.

Up to 27 months
Core Phase - Corneal cystine crystal content
Zeitfenster: Up to 27 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 27 months
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Zeitfenster: Up to 27 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 27 months
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Zeitfenster: Up to 27 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 27 months
Core Phase - Number of participants with malignancy (Cohort 1)
Zeitfenster: Up to 27 months

Number of participants with malignancy

Up to 27 months
Core Phase - Time to hematological reconstitution (Cohort 1)
Zeitfenster: Up to 24 months

Time to hematological reconstitution

Up to 24 months
Core Phase - Time to platelet engraftment (Cohort 1)
Zeitfenster: Up to 24 months

Time to platelet engraftment

Up to 24 months
Core Phase - Incidence of Adverse Events (Cohort 0)
Zeitfenster: up to 24 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

up to 24 months
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Zeitfenster: Up to 15 years and 8 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 15 years and 8 months
Extension Phase - Number of participants with malignancy (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Number of participants with malignancy

Up to 15 years and 3 months
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 15 years and 3 months
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Change from baseline on urine amino acids

Up to 15 years and 3 months
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Change from baseline on urinary glucose to creatinine ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 15 years and 3 months
Extension Phase - Duration of reversal of RFS (Cohort 1)
Zeitfenster: Up to 15 years

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 15 years
Extension Phase - Number of participants with kidney failure (Cohort 1)
Zeitfenster: Up to 15 years

Number of participants with kidney failure

Up to 15 years
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Zeitfenster: Up to 15 years

Independence from oral and ophthalmic cysteamine

Up to 15 years
Extension Phase - Corneal cystine crystal content (Cohort 1)
Zeitfenster: Up to 15 years and 3 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 15 years and 3 months
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Zeitfenster: Up to 15 years and 8 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 15 years and 8 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

2. Juni 2025

Primärer Abschluss (Geschätzt)

28. Mai 2031

Studienabschluss (Geschätzt)

28. Mai 2044

Studienanmeldedaten

Zuerst eingereicht

17. März 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. März 2025

Zuerst gepostet (Tatsächlich)

4. April 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren